Odyssey Semiconductor (ODII) 10-Q 18 Nov 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Nov. 17, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	333-234741
Entity Registrant Name	Odyssey Semiconductor Technologies, Inc.
Entity Central Index Key	0001781405
Entity Tax Identification Number	84-1766761
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	9 Brown Road
Entity Address, City or Town	Ithaca
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	14850
City Area Code	607
Local Phone Number	351-9768
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		12,726,911

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current Assets:
Cash	$ 3,409,429	$ 272,705
Contract assets		62,273
Accounts receivable	48,045	10,877
Deferred expenses	4,941	185,084
Prepaid expenses and other current assets	35,261	33,569
Total Current Assets	3,497,676	564,508
Restricted cash	103,188	103,149
Property and equipment, net	894,967	986,407
Total Assets	4,495,831	1,654,064
Current Liabilities:
Accounts payable and accrued expenses	119,205	187,046
Loan payable - short term	77,278	53,858
Deferred revenue	30,000	260,447
Total Current Liabilities	226,483	501,351
Loans payable - long term	554,853	621,600
Total liabilities	781,336	1,122,951
Commitments and contingencies (Note 8)
Stockholders’ Equity:
Preferred stock, $0.0001 par value, 5,000,000 shares authorized; 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	0	0
Common stock, $0.0001 par value, 45,000,000 shares authorized, 12,726,911 and 11,429,661 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	1,272	1,143
Additional paid-in capital	9,837,157	4,046,370
Accumulated deficit	(6,123,934)	(3,516,400)
Total Stockholders’ Equity	3,714,495	531,113
Total Liabilities and Stockholders’ Equity	$ 4,495,831	$ 1,654,064

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value per share	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value per share	$ 0.0001	$ 0.0001
Common stock, shares authorized	45,000,000	45,000,000
Common stock, shares issued	12,726,911	11,429,661
Common stock, shares outstanding	12,726,911	11,429,661

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Revenues	$ 174,952	$ 636,070	$ 693,074	$ 1,102,071
Cost of Revenues	47,969	495,915	792,239	1,106,569
Gross Profit	126,983	140,155	(99,165)	(4,498)
Operating Expenses:
Research and development	454,658	107,323	1,073,737	430,592
Selling, general, and administrative	403,441	339,090	1,658,994	869,643
Total Operating Expenses	858,099	446,413	2,732,681	1,300,235
Loss From Operations	(731,116)	(306,258)	(2,831,846)	(1,304,733)
Other Income (expense):
Other income	25,013	0	238,719	1
Interest expense	(4,560)	(893)	(14,407)	0
Total Other Income (Expense)	20,453	(893)	224,312	1
Net Loss	$ (710,663)	$ (307,151)	$ (2,607,534)	$ (1,304,732)
Net Loss Per Share:
Basic	$ (0.06)	$ (0.03)	$ (0.21)	$ (0.12)
Diluted	$ (0.06)	$ (0.03)	$ (0.21)	$ (0.12)
Weighted Average Number of Common Shares Outstanding:
Basic	12,726,911	11,199,703	12,320,979	11,173,008
Diluted	12,726,911	11,199,703	12,320,979	11,173,008

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 1,116	$ 3,017,940	$ (1,473,292)	$ 1,545,764
Balance at beginning, shares at Dec. 31, 2019	11,159,661
Stock-based compensation		63,880		63,880
Net loss three months ended September 30, 2020			(502,495)	(502,495)
Ending balance, value at Mar. 31, 2020	$ 1,116	3,081,820	(1,975,787)	1,107,149
Balance at ending, shares at Mar. 31, 2020	11,159,661
Stock-based compensation		116,613		116,613
Net loss three months ended September 30, 2020			(495,086)	(495,086)
Ending balance, value at Jun. 30, 2020	$ 1,116	3,198,433	(2,470,873)	728,676
Balance at ending, shares at Jun. 30, 2020	11,159,661
Stock-based compensation		148,781		148,781
Exercise of stock options	$ 15	230,609		230,624
Exercise of stock options, shares	153,750
Net loss three months ended September 30, 2020			(307,151)	(307,151)
Ending balance, value at Sep. 30, 2020	$ 1,131	3,577,823	(2,778,024)	800,930
Balance at ending, shares at Sep. 30, 2020	11,313,411
Beginning balance, value at Dec. 31, 2020	$ 1,143	4,046,370	(3,516,400)	531,113
Balance at beginning, shares at Dec. 31, 2020	11,429,661
Stock-based compensation		678,918		678,918
Exercise of stock options	$ 4	68,434		68,438
Exercise of stock options, shares	45,625
Sale of shares of common stock	$ 125	5,006,375		5,006,500
Sale of shares of common stock, shares	1,251,625
Costs of stock sale		(407,445)		(407,445)
Net loss three months ended September 30, 2020			(895,111)	(895,111)
Ending balance, value at Mar. 31, 2021	$ 1,272	9,392,652	(4,411,511)	4,982,413
Balance at ending, shares at Mar. 31, 2021	12,726,911
Stock-based compensation		223,155		223,155
Net loss three months ended September 30, 2020			(1,001,760)	(1,001,760)
Ending balance, value at Jun. 30, 2021	$ 1,272	9,615,807	(5,413,271)	4,203,808
Balance at ending, shares at Jun. 30, 2021	12,726,911
Stock-based compensation		221,350		221,350
Net loss three months ended September 30, 2020			(710,663)	(710,663)
Ending balance, value at Sep. 30, 2021	$ 1,272	$ 9,837,157	$ (6,123,934)	$ 3,714,495
Balance at ending, shares at Sep. 30, 2021	12,726,911

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash Flows From Operating Activities:
Net loss	$ (2,607,534)	$ (1,304,732)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,123,423	329,274
Forgiveness of PPP loan and other	(210,680)
Depreciation and amortization	124,631	72,811
Changes in operating assets and liabilities:
Contract assets	62,273	430,732
Accounts receivable	(37,168)	(184,418)
Prepaid expenses and other current assets	(1,693)	55,657
Deferred expenses	180,143	29,547
Accounts payable and accrued expenses	(67,843)	93,636
Deferred revenue	(230,447)	(106,000)
Total Adjustments	942,639	721,239
Net Cash Used In Operating Activities	(1,664,895)	(583,493)
Cash Flows Used In Investing Activities:
Purchases of property and equipment	(32,505)	(610,487)
Net Cash from Investing Activities	(32,505)	(610,487)
Cash Flows From Financing Activities:
Proceeds from sale of common stock, net of costs	4,599,055
Proceeds from government loans	193,625	684,580
Repayment of government loans	(26,956)	(1,175)
Proceeds from exercise of stock options	68,438	230,624
Payment of deferred offering costs		(40,742)
Payment of deferred loan costs		(4,560)
Net Cash Provided By Financing Activities	4,834,162	868,727
Net Increase (Decrease) In Cash and Restricted Cash	3,136,762	(325,253)
Cash and Restricted Cash - Beginning Of Period	375,855	798,283
Cash and Restricted Cash - End Of Period	3,512,617	473,030
Cash and Restricted Cash Consisted of the Following:
Cash	3,409,429	370,220
Restricted cash	103,188	102,810
Cash and Restricted Cash	3,512,617	473,030
Cash paid during the year for:
Interest	$ 6,911	$ 100

Nature of Operations and Liquid

Nature of Operations and Liquidity	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Liquidity	Note 1 – Nature of Operations and Liquidity Organization and Operations Odyssey Semiconductor Technologies, Inc. (“Odyssey Technologies”) was incorporated on April 12, 2019 under the laws of the State of Delaware. Odyssey Technologies, through its wholly-owned subsidiary, Odyssey Semiconductor, Inc. (“Odyssey Semiconductor”) and Odyssey Semiconductor’s wholly owned subsidiary, JR2J, LLC (“JR2J”) (collectively, the “Company”), is a semiconductor device company developing high-voltage power switching components and systems based on proprietary Gallium Nitride (“GaN”) processing technology. COVID-19 The extent of the impact and effects of the recent outbreak of the coronavirus (COVID-19) on the operation and financial performance of our business will depend on future developments, including the duration and spread of the outbreak, related travel advisories and restrictions, the consequential potential of staff shortages, and project development delays, all of which are highly uncertain and cannot be predicted. If demand for the Company’s services or the Company’s ability to service customers are impacted for an extended period, especially as it relates to major customers, our financial condition and results of operations may be materially adversely affected. Liquidity and Financial Condition As of September 30, 2021, the Company had a cash balance, working capital and accumulated deficit of approximately $ 3,410,000 3,270,000 6,123,934 2,600,000 The Company believes its current cash on hand is sufficient to meet its operating obligations and capital requirements for at least twelve months from the issuance of these financial statements. Thereafter, the Company may need to raise further capital through the sale of additional equity or debt securities or other debt instruments to support its future operations. The Company’s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully commercialize its products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product and service offerings. There is also no assurance that the amount of funds the Company might raise will enable the Company to complete its development initiatives or attain profitable operations. If the Company is unable to obtain additional financing on a timely basis, it may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately, the Company could be forced to discontinue its operations and liquidate.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 - Summary of Significant Accounting Policies There have been no material changes to the significant accounting policies included in the condensed consolidated financial statements as of September 30, 2021 and for the year then ended, which were previously filed, except as disclosed in this note. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of September 30, 2021 and for the nine months ended September 30, 2021 and 2020. The results of operations for the nine months ended September 30, 2021 are not necessarily indicative of the operating results for the full year ending December 31, 2021 or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related disclosures included in the Company’s Annual Report on Form 10-K for fiscal year ended December 31, 2020 which have been filed with the Securities and Exchange Commission on April 8, 2021, as amended on Form 10-K/A on May 28, 2021. Use of Estimates Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company’s significant estimates used in these financial statements include, but are not limited to, fair value calculations for equity securities, stock-based compensation, the collectability of receivables, the recoverability and useful lives of long-lived assets, and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents in the financial statements. As of September 30, 2021 and December 31, 2020, the Company had no Restricted Cash Restricted cash was comprised of cash held as a security deposit in connection with the Company’s operating lease. See Note 8 – Commitments and Contingencies - Operating Lease for additional details. Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation using the straight-line method over their estimated useful lives, once the asset is placed in service. Expenditures for maintenance and repairs, which do not extend the economic useful life of the related assets, are charged to operations as incurred, and expenditures which extend the economic life are capitalized. Leasehold improvements are depreciated over the lesser of their estimated useful lives or the remaining term of their respective lease. When assets are retired or otherwise disposed of, the costs and related accumulated depreciation or amortization are removed from the accounts and any gain or loss on disposal is recognized in the statement of operations for the respective period. The Company’s long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The estimated useful lives of property and equipment are as follows: Schedule of estimated useful lives of property and equipment Asset Useful lives (years) Computer and office equipment 5 Lab equipment 5 Leasehold improvements shorter of useful life or lease term Machinery 7 15 Furniture 7 Fair Value of Stock Options and Warrant The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued. Option forfeitures are accounted for at the time of occurrence. The expected term used is the estimated period of time that warrants or options are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” employee options. For investor warrants and non-employee options, the expected term used is the contractual life of the instrument being valued. The Company does not yet have a trading history to support its historical volatility calculations. Accordingly, the Company is utilizing an expected volatility figure based on a review of the historical volatility of comparable entities over a period of time equivalent to the expected life of the instrument being valued. Revenue Recognition The Company recognizes revenue under ASC Topic 606, “Revenue from Contracts with Customers” (“ASC 606”). The Company determines revenue recognition through the following steps: ● Step 1: ● Step 2: ● Step 3: ● Step 4: ● Step 5: A majority of the Company’s revenues are generated from contracts with customers that require it to design, develop, manufacture, test and integrate complex equipment and to provide engineering and technical services according to customer specifications. These contracts are often priced on a time and material type basis. Revenues on time and material type contracts are generally recognized in each period based on the amount billable to the customer which is based on direct labor hours expended multiplied by the contractual fixed rate per hour, plus the actual costs of materials and other direct non-labor costs. The timing of the Company’s revenue recognition may differ from the timing of payment by its customers. A receivable is recorded when revenue is recognized prior to payment and the Company has an unconditional right to payment. Alternatively, when payment precedes the provision of the related services, the Company records deferred revenue until the performance obligations are satisfied. Contract assets are comprised of unbilled contract receivables related to revenues earned but not yet invoiced to customers. During the nine months ended September 30, 2021 and 2020, there was no revenue recognized from performance obligations satisfied (or partially satisfied) in previous periods. The Company generates revenue from government contracts that reimburse the Company for certain allowable costs for funded projects. For contracts with government agencies, when the Company has concluded that it is the principal in conducting the research and development expenses and where the funding arrangement is considered central to the Company’s ongoing operations, the Company classifies the recognized funding received as revenue. The Company has determined that revenue generated from government grants is outside the scope of ASC 606 and, as a result, the Company recognizes revenue upon incurring qualifying, reimbursable expenses. During the nine months ended September 30, 2021 and 2020, the Company recognized approximately $ 418,000 900,000 0 450,000 Deferred Expenses Deferred expenses consist of labor, materials and other costs that are attributable to customer contracts that the Company has not completed its performance obligation under the contract and, as a result, has not recognized revenue. As of September 30, 2021 and December 31, 2020, deferred expenses were approximately $ 5,000 185,000 . Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Upon the exercise of an award, the Company issues new shares of common stock out of its authorized shares. Net (Loss) Income per share of Common Stock Basic net (loss) income per share of common stock is computed by dividing net (loss) income by the weighted average number of vested shares of common stock outstanding during the period. Diluted net income per share of common stock is computed by dividing net income by the weighted average number of common and dilutive common-equivalent shares outstanding during each period. The following shares were excluded from the calculation of weighted average dilutive shares of common stock because their inclusion would have been anti-dilutive: As of September 30, 2021 2020 Warrants 245,696 155,966 Options 2,042,857 1,736,250 Total 2,288,553 1,892,216 Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company has recorded a full valuation allowance against its deferred tax assets for all periods, due to the uncertainty of future utilization. The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s financial statements as of September 30, 2021 and December 31, 2020. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date. The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as selling, general and administrative expenses in the consolidated statements of operations. Recently Issued Accounting Standards In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” (“ASU 2016-02”). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. ASU 2016-02 will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The FASB issued ASU No. 2018-10 “Codification Improvements to Topic 842, Leases” (“ASU 2018-10”), ASU No. 2018-11 “Leases (Topic 842) Targeted Improvements” (“ASU 2018-11”) in July 2018, and ASU No. 2018-20 “Leases (Topic 842) - Narrow Scope Improvements for Lessors” (“ASU 2018-20”) in December 2018. ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Pursuant to ASU 2019-10 the effective date for ASC 842 was deferred an additional year. The Company expects to recognize operating lease right-of-use assets and lease liabilities on the balance sheet upon adoption of this ASU. The Company is currently evaluating these ASUs and their impact on its consolidated financial statements.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	9 Months Ended
	Sep. 30, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Note 3 - Prepaid Expenses and Other Current Assets Prepaid expenses consisted of the following: Schedule of Prepaid expenses and other current assets September 30, 2021 December 31, 2020 Insurance $ 35,261 $ 33,569 Total $ 35,261 $ 33,569

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	9 Months Ended
	Sep. 30, 2021
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	Note 4 - Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consisted of the following: Schedule of Accounts Payable and Accrued Expenses September 30, 2021 December 31, 2020 Accounts payable $ 29,850 $ 80,548 Accrued payroll 61,803 46,650 Credit cards payable 13,130 49,045 Other 14,422 10,803 Total $ 119,205 $ 187,046

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 5 – Property and Equipment Property and equipment consisted of the following: Schedule of property and equipment September 30, 2021 December 31, 2020 Computer and office equipment $ 2,807 $ 2,807 Lab equipment 15,606 15,606 Furniture 43,705 43,705 Leasehold improvements 450,374 422,318 Machinery 627,641 623,190 Subtotal 1,140,133 1,107,626 Accumulated Depreciation (245,166 ) (121,219 ) Property and Equipment, net $ 894,967 $ 986,407 Depreciation and amortization expense related to property and equipment was approximately $ 42,000 30,400 125,000 73,000

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Stockholders’ Equity	Note 6 – Stockholders’ Equity Authorized Capital The Company is authorized to issue 45,000,000 0.0001 5,000,000 0.0001 Common Stock Transactions In March 2021, the Company sold 1,251,625 4.00 5,006,500 407,445 89,730 5 4.00 480,000

Equity Compensation Plan

Equity Compensation Plan	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Equity Compensation Plan	Note 7 – Equity Compensation Plan On June 18, 2019, the Board of Directors and a majority of the Company’s shareholders, respectively, approved the 2019 Equity Compensation Plan (the “2019 Plan”). Under the 2019 Plan, 1,326,000 On March 11, 2020, the Company granted the following 10 965,850 321,950 The grant was reduced to 500,000 options, including 375,000 options and 125,000 options respectively under the two categories, due to limitations under the 2019 Plan. The terms of the 125,000 performance based options were established in the quarter ended September 30, 2020. The terms of the performance based options were met during the quarter ended March 31, 2021. On May 26, 2020, the Board of Directors and a majority of the Company’s shareholders approved an amendment to the 2019 Plan to (i) increase the number of shares of common stock authorized for issuance under the 2019 Plan by 1,174,000 shares, such that a total of 2,500,000 shares of common stock are now authorized for issuance under the 2019 Plan; (ii) increase the maximum aggregate number of shares, options and/or other awards that may be granted to any one person during any calendar year from 500,000 to 1,300,000; and (iii) clarify the availability of cashless exercise as a form of consideration. On July 16, 2020, the Company granted the following 10 1.50 600,000 200,000 On September 16, 2020, the Board of Directors and a majority of the Company’s shareholders approved an amendment to the 2019 Plan to increase the number of shares of common stock authorized for issuance under the 2019 Plan from 2,500,000 4,600,000 On September 22, 2020, the Company granted a 10 1,637,410 1.50 From June 1 to June 22, 2021, the Company granted five and 10 388,246 2.90 3.93 On September 22, 2021, upon the resignation of our then Chief Executive Officer and Chairman, a total of 1,911,160 unvested options that he received on September 25, 2019, March 11, 2020, July 16, 2020 and September 22, 2020 were forfeited as of such da te. On such date, the Company also provided the acceleration of 25,000 The stock option activity from January 1, 2021 through September 30, 2021 is as follows: Schedule of stock option activity Shares Weighted-Average Exercise Weighted-Average Remaining Balance, January 1, 2021 3,257,410 $ 1.50 9.0 Options granted 388,246 3.69 9.4 Options exercised (45,625 ) 1.50 — Options converted — — — Options forfeited or expired (1,911,160 ) 1.50 — Balance, September 30, 2021 1,688,871 $ 2.00 7.5 Vested shares at September 30, 2021 983,667 1.50 8.1 The Company has estimated the fair value of all stock option awards as of the date of grant by applying the Black-Scholes option-pricing model. In applying the Black-Scholes option pricing model, the Company used the following assumptions for 2021 and 2020 issuances: Schedule of Valuation Assumptions Risk-free interest rate 1.1 % 1.75 % Expected term 7.5 10 Expected volatility 81 % 78 % Expected dividends 0 0.00 % Grant date fair value of common stock $ 2.45 /share $ 1.50 /share During the nine months ended September 30, 2021, the Company recognized stock-based compensation expense related to stock options of approximately $ 1,123,000 1,023,000 69,000 31,000 329,000 198,000 70,000 61,000 During the three months ended September 30, 2021, the Company recognized stock-based compensation expense related to stock options of approximately $ 221,000 192,000 27,000 2,000 180,000 101,000 36,000 43,000 As of September 30, 2021, there was unamortized stock-based compensation of approximately $ 1,300,000 1.7 547,000 413,000

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 8 - Commitments and Contingencies Litigations, Claims, and Assessments From time to time, the Company is involved in various disputes, claims, liens and litigation matters arising out of the normal course of business which could result in a material adverse effect on the Company’s combined financial position, results of operations or cash flows. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. As of September 30, 2021 and December 31, 2020, the Company had no outstanding claims or litigation and had no liabilities recorded for loss contingencies. Operating Lease On August 21, 2019, the Company entered into a lease for a 10,000 square foot facility consisting of lab and office space. The lease requires monthly payments of $ 16,667 November 30, 2025 100,000 200,000 350,000

Concentrations

Concentrations	9 Months Ended
	Sep. 30, 2021
Risks and Uncertainties [Abstract]
Concentrations	Note 9 – Concentrations During the nine months ended September 30, 2021, approximately 60 During the three and nine months ended September 30, 2020, substantially all revenues were generated from a government entity pursuant to our contract with a governmental entity and amounted to approximately 60 83

Government Loans

Government Loans	9 Months Ended
	Sep. 30, 2021
Government Loans
Government Loans	Note 10 – Government Loans Paycheck Protection Program Loan On May 1, 2020, the Company received loan proceeds in the amount of approximately $ 211,000 On February 24, 2021, the Company received $ 193,625 1 monthly 3,300 Economic Injury Disaster Loan Advance On May 1, 2020, the Company received an advance in the amount of $ 10,000 138,900 monthly 678 3.75 30 Tomkins County Area Development Loan On May 27, 2020, the Company received loan proceeds in the amount of $ 50,000 2.5 monthly 1,443 E quipment Loans On August 20, 2020, the Company received a loan of $ 100,000 5 2.5 monthly 1,775 100,000 5 5.0 monthly 2,072 75,000 5 2.5 monthly 1,331 The loans are summarized as follows: Schedule of loans September 30, 2021 December 31, 2020 Principal outstanding $ 635,855 $ 679,866 Deferred loan costs, net of amortization (3,724 ) (4,408 ) Subtotal 632,131 675,458 Less current portion (77,278 ) (53,858 ) Total long term portion $ 554,853 $ 621,600 Interest expense on the above debt instruments was approximately $ 14,000 5,000 1,400

Restatement of stock compensati

Restatement of stock compensation expense	9 Months Ended
	Sep. 30, 2021
Restatement Of Stock Compensation Expense
Restatement of stock compensation expense	Note 11 – Restatement of stock compensation expense In calculating our stock based compensation expense for the quarter ended June 30, 2021, we identified errors in our previously issued financial statements as of June 30, 2021 related to the measurement of vested stock options. We assessed the materiality of this error in accordance with the U.S. Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”) No. 99, “Materiality” and SAB No. 108, “Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements” (“SAB 108”), using both the rollover method and the iron curtain method, as defined in SAB 108, and concluded the error were immaterial to the prior period but, if corrected in the current period, would have been material to the current quarter. Under SAB 108, such prior-period misstatements which, if corrected in the current period would be material to the current period, must be corrected by adjusting the prior-period financial statements. Correcting prior-period financial statements for such immaterial misstatements does not require previously filed reports to be amended. For the three and six months ended June 30, 2021, correction of this error decreased our stock based compensation expense, general and administrative expenses, total operating expenses and net loss by $ 313,323 0.02 0.08 313,323

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 12 - Subsequent Events The Company has evaluated events that have occurred after the balance sheet and through November 17, 2021. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of September 30, 2021 and for the nine months ended September 30, 2021 and 2020. The results of operations for the nine months ended September 30, 2021 are not necessarily indicative of the operating results for the full year ending December 31, 2021 or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related disclosures included in the Company’s Annual Report on Form 10-K for fiscal year ended December 31, 2020 which have been filed with the Securities and Exchange Commission on April 8, 2021, as amended on Form 10-K/A on May 28, 2021.
Use of Estimates	Use of Estimates Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company’s significant estimates used in these financial statements include, but are not limited to, fair value calculations for equity securities, stock-based compensation, the collectability of receivables, the recoverability and useful lives of long-lived assets, and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents in the financial statements. As of September 30, 2021 and December 31, 2020, the Company had no
Restricted Cash	Restricted Cash Restricted cash was comprised of cash held as a security deposit in connection with the Company’s operating lease. See Note 8 – Commitments and Contingencies - Operating Lease for additional details.
Property and Equipment	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation using the straight-line method over their estimated useful lives, once the asset is placed in service. Expenditures for maintenance and repairs, which do not extend the economic useful life of the related assets, are charged to operations as incurred, and expenditures which extend the economic life are capitalized. Leasehold improvements are depreciated over the lesser of their estimated useful lives or the remaining term of their respective lease. When assets are retired or otherwise disposed of, the costs and related accumulated depreciation or amortization are removed from the accounts and any gain or loss on disposal is recognized in the statement of operations for the respective period. The Company’s long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The estimated useful lives of property and equipment are as follows: Schedule of estimated useful lives of property and equipment Asset Useful lives (years) Computer and office equipment 5 Lab equipment 5 Leasehold improvements shorter of useful life or lease term Machinery 7 15 Furniture 7
Fair Value of Stock Options and Warrant	Fair Value of Stock Options and Warrant The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued. Option forfeitures are accounted for at the time of occurrence. The expected term used is the estimated period of time that warrants or options are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” employee options. For investor warrants and non-employee options, the expected term used is the contractual life of the instrument being valued. The Company does not yet have a trading history to support its historical volatility calculations. Accordingly, the Company is utilizing an expected volatility figure based on a review of the historical volatility of comparable entities over a period of time equivalent to the expected life of the instrument being valued.
Revenue Recognition	Revenue Recognition The Company recognizes revenue under ASC Topic 606, “Revenue from Contracts with Customers” (“ASC 606”). The Company determines revenue recognition through the following steps: ● Step 1: ● Step 2: ● Step 3: ● Step 4: ● Step 5: A majority of the Company’s revenues are generated from contracts with customers that require it to design, develop, manufacture, test and integrate complex equipment and to provide engineering and technical services according to customer specifications. These contracts are often priced on a time and material type basis. Revenues on time and material type contracts are generally recognized in each period based on the amount billable to the customer which is based on direct labor hours expended multiplied by the contractual fixed rate per hour, plus the actual costs of materials and other direct non-labor costs. The timing of the Company’s revenue recognition may differ from the timing of payment by its customers. A receivable is recorded when revenue is recognized prior to payment and the Company has an unconditional right to payment. Alternatively, when payment precedes the provision of the related services, the Company records deferred revenue until the performance obligations are satisfied. Contract assets are comprised of unbilled contract receivables related to revenues earned but not yet invoiced to customers. During the nine months ended September 30, 2021 and 2020, there was no revenue recognized from performance obligations satisfied (or partially satisfied) in previous periods. The Company generates revenue from government contracts that reimburse the Company for certain allowable costs for funded projects. For contracts with government agencies, when the Company has concluded that it is the principal in conducting the research and development expenses and where the funding arrangement is considered central to the Company’s ongoing operations, the Company classifies the recognized funding received as revenue. The Company has determined that revenue generated from government grants is outside the scope of ASC 606 and, as a result, the Company recognizes revenue upon incurring qualifying, reimbursable expenses. During the nine months ended September 30, 2021 and 2020, the Company recognized approximately $ 418,000 900,000 0 450,000
Deferred Expenses	Deferred Expenses Deferred expenses consist of labor, materials and other costs that are attributable to customer contracts that the Company has not completed its performance obligation under the contract and, as a result, has not recognized revenue. As of September 30, 2021 and December 31, 2020, deferred expenses were approximately $ 5,000 185,000 .
Stock-Based Compensation	Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Upon the exercise of an award, the Company issues new shares of common stock out of its authorized shares.
Net (Loss) Income per share of Common Stock	Net (Loss) Income per share of Common Stock Basic net (loss) income per share of common stock is computed by dividing net (loss) income by the weighted average number of vested shares of common stock outstanding during the period. Diluted net income per share of common stock is computed by dividing net income by the weighted average number of common and dilutive common-equivalent shares outstanding during each period. The following shares were excluded from the calculation of weighted average dilutive shares of common stock because their inclusion would have been anti-dilutive: As of September 30, 2021 2020 Warrants 245,696 155,966 Options 2,042,857 1,736,250 Total 2,288,553 1,892,216
Income Taxes	Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company has recorded a full valuation allowance against its deferred tax assets for all periods, due to the uncertainty of future utilization. The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s financial statements as of September 30, 2021 and December 31, 2020. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date. The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as selling, general and administrative expenses in the consolidated statements of operations.
Recently Issued Accounting Standards	Recently Issued Accounting Standards In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” (“ASU 2016-02”). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. ASU 2016-02 will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The FASB issued ASU No. 2018-10 “Codification Improvements to Topic 842, Leases” (“ASU 2018-10”), ASU No. 2018-11 “Leases (Topic 842) Targeted Improvements” (“ASU 2018-11”) in July 2018, and ASU No. 2018-20 “Leases (Topic 842) - Narrow Scope Improvements for Lessors” (“ASU 2018-20”) in December 2018. ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Pursuant to ASU 2019-10 the effective date for ASC 842 was deferred an additional year. The Company expects to recognize operating lease right-of-use assets and lease liabilities on the balance sheet upon adoption of this ASU. The Company is currently evaluating these ASUs and their impact on its consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Schedule of estimated useful lives of property and equipment	Schedule of estimated useful lives of property and equipment Asset Useful lives (years) Computer and office equipment 5 Lab equipment 5 Leasehold improvements shorter of useful life or lease term Machinery 7 15 Furniture 7
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	As of September 30, 2021 2020 Warrants 245,696 155,966 Options 2,042,857 1,736,250 Total 2,288,553 1,892,216

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Prepaid expenses and other current assets	Schedule of Prepaid expenses and other current assets September 30, 2021 December 31, 2020 Insurance $ 35,261 $ 33,569 Total $ 35,261 $ 33,569

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2021
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Expenses	Schedule of Accounts Payable and Accrued Expenses September 30, 2021 December 31, 2020 Accounts payable $ 29,850 $ 80,548 Accrued payroll 61,803 46,650 Credit cards payable 13,130 49,045 Other 14,422 10,803 Total $ 119,205 $ 187,046

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	Schedule of property and equipment September 30, 2021 December 31, 2020 Computer and office equipment $ 2,807 $ 2,807 Lab equipment 15,606 15,606 Furniture 43,705 43,705 Leasehold improvements 450,374 422,318 Machinery 627,641 623,190 Subtotal 1,140,133 1,107,626 Accumulated Depreciation (245,166 ) (121,219 ) Property and Equipment, net $ 894,967 $ 986,407

Equity Compensation Plan (Table

Equity Compensation Plan (Tables)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Schedule of stock option activity	Schedule of stock option activity Shares Weighted-Average Exercise Weighted-Average Remaining Balance, January 1, 2021 3,257,410 $ 1.50 9.0 Options granted 388,246 3.69 9.4 Options exercised (45,625 ) 1.50 — Options converted — — — Options forfeited or expired (1,911,160 ) 1.50 — Balance, September 30, 2021 1,688,871 $ 2.00 7.5 Vested shares at September 30, 2021 983,667 1.50 8.1
Schedule of Valuation Assumptions	Schedule of Valuation Assumptions Risk-free interest rate 1.1 % 1.75 % Expected term 7.5 10 Expected volatility 81 % 78 % Expected dividends 0 0.00 % Grant date fair value of common stock $ 2.45 /share $ 1.50 /share

Government Loans (Tables)

Government Loans (Tables)	9 Months Ended
	Sep. 30, 2021
Government Loans
Schedule of loans	Schedule of loans September 30, 2021 December 31, 2020 Principal outstanding $ 635,855 $ 679,866 Deferred loan costs, net of amortization (3,724 ) (4,408 ) Subtotal 632,131 675,458 Less current portion (77,278 ) (53,858 ) Total long term portion $ 554,853 $ 621,600

Nature of Operations and Liqu_2

Nature of Operations and Liquidity (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash balance	$ 3,410,000
Working capital	3,270,000
Retained Earnings (Accumulated Deficit)	6,123,934	$ (313,323)	$ 3,516,400
Net income loss	$ 2,600,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details)	9 Months Ended
	Sep. 30, 2021
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful lives	5 years
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful lives	5 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful lives	shorter of useful life or lease term
Machinery [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful lives	7 years
Machinery [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful lives	15 years
Furniture [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful lives	7 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	2,288,553	1,892,216
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	245,696	155,966
Options Held [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	2,042,857	1,736,250

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Accounting Policies [Abstract]
Cash equivalents	$ 0		$ 0		$ 0
Grant Revenue	0	$ 450,000	418,000	$ 900,000
Deferred expenses	$ 5,000		$ 5,000		$ 185,000

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Insurance	$ 35,261	$ 33,569
Total	$ 35,261	$ 33,569

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Accounts payable	$ 29,850	$ 80,548
Accrued payroll	61,803	46,650
Credit cards payable	13,130	49,045
Other	14,422	10,803
Total	$ 119,205	$ 187,046

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Subtotal	$ 1,140,133	$ 1,107,626
Accumulated Depreciation	(245,166)	(121,219)
Property and Equipment, net	894,967	986,407
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Subtotal	2,807	2,807
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Subtotal	15,606	15,606
Furniture [Member]
Property, Plant and Equipment [Line Items]
Subtotal	43,705	43,705
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Subtotal	450,374	422,318
Machinery [Member]
Property, Plant and Equipment [Line Items]
Subtotal	$ 627,641	$ 623,190

Property and Equipment (Detai_2

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 42,000	$ 30,400	$ 125,000	$ 73,000

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Mar. 31, 2021	Mar. 31, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized			45,000,000		45,000,000
Common stock, par value per share			$ 0.0001		$ 0.0001
Preferred stock, shares authorized			5,000,000		5,000,000
Preferred stock, par value per share			$ 0.0001		$ 0.0001
Proceeds from stock of sold			$ 4,599,055
Proceeds from related parties	$ 480,000
Common Stock [Member] | Private Placement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of stock sold		1,251,625
Exercise Price		$ 4
Proceeds from stock of sold		$ 5,006,500
Proceeds from warrant exercised		$ 407,445
Number of warrant purchased		89,730
Warrant term	5 years	5 years
Share price	$ 4	$ 4

Equity Compensation Plan (Detai

Equity Compensation Plan (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Equity [Abstract]
Options Outstanding, Beginning	3,257,410
Options Outstanding, Beginning	$ 1.50
Options Outstanding, Beginning		9 years
Options Granted	388,246
Options Granted	$ 3.69
Options Outstanding, granted	9 years 4 months 24 days
Options Exercised	(45,625)
Options Exercised	$ 1.50
Options converted	0
Options converted	$ 0
Options forfeited or expired	(1,911,160)
Options forfeited or expired	$ 1.50
Options Outstanding, Ending	1,688,871	3,257,410
Options Outstanding, Ending	$ 2	$ 1.50
Options Outstanding, Ending	7 years 6 months
Vested shares at period end	983,667
Vested shares, at period end	$ 1.50
Options vested	8 years 1 month 6 days

Equity Compensation Plan (Det_2

Equity Compensation Plan (Details 1) - $ / shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Equity [Abstract]
Risk-free interest rate	1.10%	1.75%
Expected term	7 years 6 months	10 years
Expected volatility	81.00%	78.00%
Expected dividends	0.00%	0.00%
Grant date fair value of common stock	$ 2.45	$ 1.50

Equity Compensation Plan (Det_3

Equity Compensation Plan (Details Narrative) - USD ($)

Mar. 11, 2020

Jun. 22, 2021

Sep. 22, 2020

Jul. 16, 2020

Mar. 26, 2020

Sep. 30, 2021

Sep. 30, 2020

Sep. 30, 2021

Sep. 30, 2020

Sep. 25, 2021

Sep. 22, 2021

Sep. 16, 2020

Sep. 15, 2020

Jun. 18, 2019

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock-based compensation expense

$ 221,000

$ 180,000

$ 1,123,000

$ 329,000

General and administrative expenses

192,000

101,000

1,023,000

198,000

Research and development expenses

27,000

36,000

69,000

70,000

Cost of revenues

2,000

$ 43,000

31,000

$ 61,000

Unamortized stock-based compensation

1,300,000

$ 1,300,000

Unamortized stock-based compensation period

1 year 8 months 12 days

Intrinsic value of outstanding

547,000

$ 547,000

Intrinsic value of vested stock options

$ 413,000

$ 413,000

Chief Executive Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Unvested options

25,000

1,911,160

Options Held [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Option grant term

10 years

Option granted

388,246

Equity Compensation Plan description

The grant was reduced to 500,000 options, including 375,000 options and 125,000 options respectively under the two categories, due to limitations under the 2019 Plan. The terms of the 125,000 performance based options were established in the quarter ended September 30, 2020. The terms of the performance based options were met during the quarter ended March 31, 2021.

Board of Directors and a majority of the Company’s shareholders approved an amendment to the 2019 Plan to (i) increase the number of shares of common stock authorized for issuance under the 2019 Plan by 1,174,000 shares, such that a total of 2,500,000 shares of common stock are now authorized for issuance under the 2019 Plan; (ii) increase the maximum aggregate number of shares, options and/or other awards that may be granted to any one person during any calendar year from 500,000 to 1,300,000; and (iii) clarify the availability of cashless exercise as a form of consideration.

Options Held [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Option exercise price

$ 2.90

Options Held [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Option exercise price

$ 3.93

Options Held [Member] | Executive Chairman [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Option grant term

10 years

10 years

Option granted

965,850

600,000

Option exercise price

$ 1.50

Options Held [Member] | Chief Executive Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Option grant term

10 years

Option granted

321,950

1,637,410

200,000

Option exercise price

$ 1.50

N 2019 Equity Compensation Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of Shares Authorized

1,326,000

Amended N 2019 Equity Compensation Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of Shares Authorized

4,600,000

2,500,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Periodic payments	$ 16,667
Lease expiration date	Nov. 30, 2025
Letter of credit	$ 100,000	$ 100,000
Minimum lease payments for 2020	200,000
Minimum lease payments for 2021	200,000
Minimum lease payments for 2022	200,000
Minimum lease payments for 2023	200,000
Minimum lease payments for thereafter	$ 350,000

Concentrations (Details Narrati

Concentrations (Details Narrative)	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue Benchmark [Member] | Entities A [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	60.00%	60.00%	83.00%

Government Loans (Details)

Government Loans (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Government Loans
Principal outstanding	$ 635,855	$ 679,866
Deferred loan costs, net of amortization	(3,724)	(4,408)
Subtotal	632,131	675,458
Less current portion	(77,278)	(53,858)
Total long term portion	$ 554,853	$ 621,600

Government Loans (Details Narra

Government Loans (Details Narrative) - USD ($)	May 01, 2020	Feb. 24, 2021	Sep. 02, 2020	Aug. 30, 2020	Aug. 28, 2020	Aug. 20, 2020	May 27, 2020	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
Debt Instrument [Line Items]
Proceeds from loan									$ 193,625	$ 684,580
Interest expense								$ 5,000	$ 14,000	$ 1,400
Small Business Administration [Member]
Debt Instrument [Line Items]
Proceeds from loan	$ 10,000			$ 138,900
Interest rate				3.75%
Frequency of payment				monthly
Periodic payments				$ 678
Loan term				30 years
Tomkins County Area Development [Member]
Debt Instrument [Line Items]
Proceeds from loan					$ 75,000		$ 50,000
Interest rate					2.50%		2.50%
Frequency of payment					monthly		monthly
Periodic payments					$ 1,331		$ 1,443
Loan term					5 years
Paycheck Protection Program [Member]
Debt Instrument [Line Items]
Proceeds from loan	$ 211,000
Paycheck Protection Program 2 [Member]
Debt Instrument [Line Items]
Proceeds from loan		$ 193,625
Interest rate		1.00%
Frequency of payment		monthly
Periodic payments		$ 3,300
Equipment Loans [Member]
Debt Instrument [Line Items]
Proceeds from loan						$ 100,000
Interest rate						2.50%
Frequency of payment						monthly
Periodic payments						$ 1,775
Loan term						5 years
Southern Tier Region Economic Development Corporation [Member]
Debt Instrument [Line Items]
Proceeds from loan			$ 100,000
Interest rate			5.00%
Frequency of payment			monthly
Periodic payments			$ 2,072
Loan term			5 years

Restatement of stock compensa_2

Restatement of stock compensation expense (Details Narrative) - USD ($)	3 Months Ended			6 Months Ended	9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2020	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Restatement Of Stock Compensation Expense
Net loss	$ 710,663	$ 313,323	$ 307,151	$ 313,323	$ 2,607,534	$ 1,304,732
Loss per share		$ 0.08		$ 0.02
Accumulated deficit	$ (6,123,934)	$ 313,323		$ 313,323	$ (6,123,934)		$ (3,516,400)